443 related articles for article (PubMed ID: 17085665)
21. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
22. [Determination of renal function in clinical routine: which is the best method?].
Saile P; Fiedler R; Markau S; Kuhn C; Osten B
Dtsch Med Wochenschr; 2007 May; 132(20):1093-7. PubMed ID: 17492567
[TBL] [Abstract][Full Text] [Related]
23. [Estimating renal function based on creatinine clearance: application of different formulas and correction for obese patients].
Apperloo JJ; Gerlag PG; Beerenhout CH; Vader HL
Ned Tijdschr Geneeskd; 2007 May; 151(18):1016-23. PubMed ID: 17508688
[TBL] [Abstract][Full Text] [Related]
24. Validation of a new plasma cystatin C-based formula and the Modification of Diet in Renal Disease creatinine-based formula for determination of glomerular filtration rate.
Sterner G; Björk J; Carlson J; Grubb A; Nyman U
Scand J Urol Nephrol; 2009; 43(3):242-9. PubMed ID: 19291590
[TBL] [Abstract][Full Text] [Related]
25. Determination of lowest possible creatinine in living-donor kidney renal transplant recipients based on donor kidney function.
Sberro R; Zuber J; Froissart M; Canaud G; Prié D; Martinez F; Mamzer-Bruneel MF; Anglicheau D; Legendre C; Thervet E
Transplantation; 2008 Aug; 86(4):558-63. PubMed ID: 18724226
[TBL] [Abstract][Full Text] [Related]
26. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
27. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
28. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
29. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin.
Jennings S; de Lemos ML; Levin A; Murray N
J Oncol Pharm Pract; 2010 Jun; 16(2):113-9. PubMed ID: 19578094
[TBL] [Abstract][Full Text] [Related]
33. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance.
Karstila K; Harmoinen AP; Lehtimäki TJ; Korpela MM; Mustonen JT; Saha HH
Nephron Clin Pract; 2008; 108(4):c284-90. PubMed ID: 18434750
[TBL] [Abstract][Full Text] [Related]
34. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients.
Launay-Vacher V; Izzedine H; Rey JB; Rixe O; Chapalain S; Nourdine S; Paci A; Bourget P; Deray G
Med Sci Monit; 2004 May; 10(5):CR209-12. PubMed ID: 15114271
[TBL] [Abstract][Full Text] [Related]
35. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function.
Spruill WJ; Wade WE; Cobb HH
Am J Geriatr Pharmacother; 2008 Aug; 6(3):153-60. PubMed ID: 18775390
[TBL] [Abstract][Full Text] [Related]
36. Estimation of renal function -- what is appropriate in cancer patients?
Barraclough LH; Field C; Wieringa G; Swindell R; Livsey JE; Davidson SE
Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):721-6. PubMed ID: 18995170
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.
Hermsen ED; Maiefski M; Florescu MC; Qiu F; Rupp ME
Pharmacotherapy; 2009 Jun; 29(6):649-55. PubMed ID: 19476418
[TBL] [Abstract][Full Text] [Related]
38. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.
Cathomas R; Klingbiel D; Geldart TR; Mead GM; Ellis S; Wheater M; Simmonds P; Nagaraj N; von Moos R; Fehr M
Ann Oncol; 2014 Aug; 25(8):1591-7. PubMed ID: 24669017
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
40. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
Rashid ST; Salman M; Agarwal S; Hamilton G
Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
